Skip to main content
Contact Us
Subscribe
E-Edition
34°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Neuropathix, Inc.
Neuropathix, Inc. Highlights Revenue Related to its Grant Award with NIH-NINDS
May 25, 2022
From
Neuropathix, Inc.
Via
AccessWire
Exposures
COVID-19
Tickers
NPTX
Neuropathix, Inc. Highlights Positive Preclinical Study Results on Lead Drug Candidate KLS-13019
April 13, 2022
From
Neuropathix, Inc.
Via
AccessWire
Tickers
NPTX
Neuropathix, Inc. CEO Issues New Letter to Shareholders; Updates Market on Milestones in Research and Funding
April 06, 2022
From
Neuropathix, Inc.
Via
AccessWire
Tickers
NPTX
Neuropathix, Inc. Welcomes Daniele Piomelli, PhD, MD to the Company’s Scientific Advisory Board
January 25, 2022
From
Neuropathix, Inc.
Via
AccessWire
Topics
Cannabis
Derivatives
Intellectual Property
Exposures
Cannabis
Derivatives
Intellectual Property
Tickers
NPTX
Neuropathix, Inc. Receives Patent Grant from India for Its Novel Anti-Inflammatory Compounds
January 18, 2022
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
NPTX
Neuropathix, Inc. Chooses Purisys for Process Optimization and Scale Up of Its Lead Drug Candidate KLS-13019
November 17, 2021
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
NPTX
Neuropathix, Inc. Wholly Owned Subsidiary Kannalife Sciences, Inc. Awarded $2.97 Million Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS)
September 28, 2021
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Tickers
NPTX
Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
August 24, 2021
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
NPTX
Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
August 12, 2021
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
NPTX
Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
July 20, 2021
From
Neuropathix, Inc.
Via
AccessWire
Topics
Intellectual Property
Exposures
Intellectual Property
Tickers
NPTX
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.